Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AmnioGel
- Development stage
- Preclinical
- Lead developer
- Université de Genève
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Implant, Subcutaneous
01
Overview
AmnioGel is a clinically scalable, extracellular matrix (ECM)-mimetic hydrogel derived from human amniotic membrane (hAM). Developed by researchers at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) under the EU-funded VANGUARD project, AmnioGel serves as a biocompatible biological scaffold designed to support cell transplantation therapies, particularly for type 1 diabetes. By recreating the native islet microenvironment, AmnioGel promotes the survival, maturation, and function of transplanted pancreatic islets or stem cell-derived islet organoids. It facilitates the self-assembly of a microvascular network when co-encapsulated with endothelial cells (such as blood outgrowth endothelial cells), which rapidly integrates with the host vasculature post-implantation to ensure sustained nutrient delivery and glycemic control. Additionally, AmnioGel provides partial immune shielding, reducing the migration of cytotoxic immune cells and potentially eliminating the need for chronic immunosuppression.
- Other names
- Amniogelamniotic membrane-derived hydrogelhuman amniotic membrane-derived hydrogel
Beyond the preview
Go deeper on AmnioGel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmnioGel.